Finishing their phase III trial is something many of us doubted would ever happen but finally it has. Most holders already know that, scientifically, artimist will be more effective than IV and the trial is powered as such enrolling 150 patients so we can look forward to a positive trial result. What happens from here is anyone's guess. If the daytraders catch on we can see some significant action and this news is strong enough to drive that possibility. good luck to all long term holders. Your patience should see you well rewarded
EMS Price at posting:
2.4¢ Sentiment: None Disclosure: Held
